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Abstract
Introduction—The purpose of this study is to investigate comorbidity status and its impact on 
total medical expenditures in non-institutionalized hypertensive adults in the U.S.
Methods—Data from the 2011–2014 Medical Expenditure Panel Survey were used. Patients 
were included if they had a diagnosis code for hypertension, were aged ≥18 years, and were not 
pregnant during the study period (N=26,049). The Elixhauser Comorbidity Index was modified to 
add hypertension-related comorbidities. The outcome variable was annual total medical 
expenditures, and a generalized linear model regression (gamma distribution with a log link 
function) was used. All costs were adjusted to 2014 U.S. dollars.
Results—Based on the modified Elixhauser Comorbidity Index, 14.0% of patients did not have 
any comorbidities, 23.0% had one, 24.4% had two, and 38.7% had three or more. The five most 
frequent comorbidities were hyperlipidemia, diabetes, rheumatoid arthritis, depression, and 
chronic pulmonary disease. Estimated mean annual total medical expenditures were $3,914 (95% 
CI= $3,456, $4,372) for those without any comorbidity; $5,798 (95% CI=$5,384, $6,213) for 
those with one comorbidity; $8,333 (95% CI=$7,821, $8,844) for those with two comorbidities; 
and $13,920 (95% CI=$13,166, $14,674) for those with three or more comorbidities. Of the 15 
most frequent comorbidities, the condition with the largest impact on expenditures for an 
individual person was congestive heart failure ($7,380). Hypertensive adults with stroke, coronary 
heart disease, diabetes, renal diseases, and hyperlipidemia had expenditures that were $6,069, 
$6,046, $5,039, $4,974, and $4,851 higher, respectively, than those without these conditions.
Conclusions—Comorbidities are highly prevalent among hypertensive adults, and this study 
shows that each comorbidity significantly increases annual total medical expenditures.
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INTRODUCTION
Hypertension is a highly prevalent health condition; approximately one third of U.S. adults 
have this problem.1 Previous studies have provided estimates of the economic burden of 
hypertension2–13; the American Heart Association estimated that the national annual direct 
and indirect costs of hypertension were $47.3 billion and $3.9 billion (average annual 2012–
2013).3 Annual costs for the treatment of hypertension were estimated to be $812 per adult 
in 2014.14 However, most adults have been diagnosed with more than one chronic condition, 
and relatively few suffer from hypertension exclusively.15 Additionally, hypertension is a 
major risk factor for many costly chronic conditions, such as heart disease and stroke.
Multimorbidity is considered the presence of multiple diseases in an individual.16 A study 
found that approximately one fourth of the population had multimorbidity.17 Multimorbidity 
is an issue for the management of hypertension. Among elderly patients with hypertension, 
43% had two or fewer coexisting chronic conditions, 34% had three to four, and 23% had 
five or more such conditions.15
Although earlier studies have estimated the economic burden of hypertension, little is known 
about the effect of having multiple comorbidities on medical expenditures in adults with 
hypertension. The objectives of the present study are to describe comorbidity status among 
non-institutionalized adults with hypertension and to estimate annual medical expenditures 
according to the presence of comorbidities in this population.
METHODS
Data from the 2011–2014 Medical Expenditure Panel Survey (MEPS) were used for this 
analysis. MEPS is a nationally representative survey of the U.S. civilian non-
institutionalized population that provides comprehensive information on healthcare 
utilization and costs under the U.S. healthcare system. MEPS data have been used 
extensively for studying medical expenditures for various health conditions, including 
hypertension and cardiovascular disease (CVD).18–22 The MEPS data on medical conditions 
were used to define hypertension and comorbidities based on ICD-9 codes. The MEPS full-
year consolidated data were employed to define medical expenditures and patient 
characteristics.
Study Population
Adults with hypertension were included if they met all of the following criteria: any 
diagnosis codes for hypertension (ICD-9 codes: 401–405); age ≥18 years; and were not 
pregnant during the study period. Among pregnant women, hypertension and gestation 
hypertension might affect the use and cost of medical services differently from the general 
population. A total of 26,049 persons were included.
Measures
Various comorbidity indices have been developed to measure important coexisting medical 
conditions. The Elixhauser Comorbidity Index (EI) is one of the most frequently used and 
validated comorbidity indices, and the original EI includes a set of 30 conditions that are 
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coded as present or absent to produce 30 binary variables.23 In addition, the score version of 
the EI has also been validated.24,25 The score version of the EI was used to measure 
comorbidity because it is better than the original version for exploring individual 
comorbidity status and the impact of individual comorbidity on medical expenditures. In 
addition, using the score version of the EI has been validated by its ability to outperform the 
Charlson Comorbidity Index, the most commonly used comorbidity index.26–34
The authors expanded the EI to better analyze the impact of hypertension-related 
comorbidities on medical expenditures by including a broader range of CVD-related 
conditions than the original EI. First, 27 conditions from the original version of the EI 
indicators were obtained. These modifications included excluding hypertension; combining 
two types of diabetes (diabetes with complication and diabetes without complication) into 
one condition (diabetes); and combining two types of anemia (blood loss anemia and 
deficiency anemia) into one condition (anemia). Second, three conditions were added: 
coronary heart disease (CHD); stroke; and hyperlipidemia. Finally, two conditions were 
redefined: renal failure to renal disease, and arrhythmia to heart rhythm disorders. In sum, a 
total of 30 possible comorbidities were included, as follows:
• CVD and hypertension-related conditions: congestive heart failure (CHF), heart 
rhythm disorders, valvular disease, CHD, stroke, hyperlipidemia, pulmonary 
circulation disorders, peripheral vascular disorders, diabetes, renal disease, 
obesity, and depression; and
• other conditions: paralysis, neurologic disorders, hypothyroidism, liver disease, 
peptic ulcer, HIV/AIDS, lymphoma, metastatic cancer, solid tumor, rheumatoid 
arthritis, coagulopathy, weight loss, fluid and electrolyte disorders, anemia, 
alcohol abuse, drug abuse, psychoses, and chronic pulmonary disease.
The modified EI score was defined as the sum of each of the 30 comorbidities, with a 
possible range of 0–30. Depression was included in the CVD and hypertension-related 
conditions based on the results of previous meta-analyses on the association of hypertension 
with depression.35,36 Appendix Table 1 (available online) shows the list of the comorbidities 
and the ICD-9 code for each condition.
The outcome variable was annual total medical expenditures that were not specifically 
related to hypertension diagnosis or management. The expenditures included those for 
inpatient hospitalizations, outpatient visits, emergency department visits, office-based 
physician visits, home healthcare visits, and prescription medications. The annual medical 
expenditures included the total of all expenditures paid by all payers, including Medicare, 
Medicaid, other public insurance, private insurance, and payments made by the adult with 
hypertension or that person’s family during the calendar year. In terms of cost of illness 
studies, the perspective for this study was that of the healthcare sector as a whole, with 
expenditures used as a proxy for costs. All costs were adjusted to 2014 U.S. dollars using the 
personal consumption expenditure index–health by function. Ten covariates were included: 
age group, gender, race/ethnicity, U.S. region, insurance type, marital status, education level, 
poverty level, smoking status, and health status.
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Statistical Analysis
Bivariate analyses were conducted to assess the associations between personal 
characteristics and the EI. Chi-square tests were used for the categorical variables for the 
population’s characteristics, and ANOVA was used for the continuous variables. Descriptive 
statistics were employed to describe the frequencies of comorbidities.
A generalized linear model regression (gamma distribution with a log link function) was 
used to estimate the associations between the modified EI and total medical expenditures 
while controlling for covariates. A log link and gamma distribution was selected because the 
distribution of medical expenditures was positively skewed, and 99% of the sample had 
positive medical expenditures. Mean annual medical expenditures by the EI score were 
predicted using the average marginal effects method from the model. All analyses were 
performed using SAS, version 9.3, and Stata/SE, version 14.
RESULTS
A total of 26,049 patients were included in this study. Table 1 shows the characteristics of 
U.S. hypertensive adults by the modified EI. The weighted average estimate of the number 
of U.S. hypertensive adults was 64,147,867 per year, and the weighted percentage of 
hypertension in the population of interest was 27.8%.
In all, 14.0% of U.S hypertensive adults did not have any comorbidity (n=4,073), whereas 
23.0% had one (n=6,135); 24.4% had two (n=6,310); and 38.7% had three or more 
(n=9,531). Figure 1 shows the percentages of the 15 most frequent comorbidities in U.S 
hypertensive adults, which were hyperlipidemia, diabetes, rheumatoid arthritis, depression, 
chronic pulmonary disease, CHD, hypothyroidism, renal disease, solid tumor, heart rhythm 
disorders, stroke, neurologic disorders, fluid and electrolyte disorders, CHF, and valvular 
heart disease.
Table 2 shows the estimated total medical expenditures by personal descriptors and the 
number of comorbidities in U.S. hypertensive adults. Overall, the mean annual medical 
expenditure was $9,841 (95% CI=$9,464, $10,218). The comorbidity score was positively 
associated with the estimated mean annual total medical expenditures. Estimates were 
$3,914 (95% CI=$3,456, $4,372) for those without any comorbidity; $5,798 (95% CI=
$5,384, $6,213) for those with one; $8,333 (95% CI= $7,821, $8,844) for those with two; 
and $13,920 (95% CI=$13,166, $14,674) for those with three or more comorbidities. 
Appendix Table 2 (available online) describes generalized linear model estimates and 
associated p-values for total medical expenditures.
Figure 2 shows the estimated medical expenditures by the presence of nine hypertension-
related comorbidities among the 15 most frequent comorbidities. The impact of 
comorbidities on medical expenditures varied by type, with CHF associated with the largest 
impact on expenditures. Annual total medical expenditures were $17,063 (95% CI=$16,224, 
$17,902) in persons with CHF versus $9,683 (95% CI=$9,313, $10,053) in persons without 
CHF, a difference of $7,380. The increased medical expenditures from specific 
comorbidities were $6,069 for stroke, $6,046 for CHD, $5,093 for heart rhythm disorders, 
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$4,851 for hyperlipidemia, and $4,453 for valvular disease. Diabetes, renal disease, and 
depression each increased expenditures by ≅$5,000. Appendix Table 3 (available online) 
describes the differences in estimated annual medical expenditures by the presence of 
comorbidities.
DISCUSSION
The present study used a nationally representative sample of the U.S. population to estimate 
medical expenditures in hypertensive adults according to comorbidity status. To the authors’ 
knowledge, this is the first study that provides insight into the economic burden of 
hypertension by comorbidity status. Overall, as expected, the study found that a higher 
comorbidity score was associated with higher total medical expenditures in adults with 
hypertension. In addition, the differences in expenditures varied by type of comorbidity.
Also as expected, having incrementally more total comorbidities was associated with 
increasing medical expenditures. In non-hypertensive adults without any of the listed 
comorbidities, annual total medical expenditures were $1,656 (authors’ calculation from the 
2011–2014 MEPS), which could reflect the use of preventive services or medical services 
for other conditions that were not included in the modified EI. Thus, having hypertension 
alone added $2,258 per year, because annual medical expenditures were $3,914 in 
hypertensive adults without any comorbidities included in the EI, and this figure increased to 
$13,920 in those with three or more comorbidities included in the EI. The findings of the 
present study extend this work to pinpoint even further which American adults with 
hypertension generally incur the highest expenses for medical care.
Hyperlipidemia, CHD, heart rhythm disorders, CHF, valvular disease, and stroke were 
classified in this study as comorbidities related to CVD. Notably, all six CVD-related 
comorbidities emerged in the list of the 15 most frequent comorbidities in the population of 
interest.
Hyperlipidemia was the most frequent comorbidity in adults with hypertension in this study, 
indicating more than half of adults with hypertension had hyperlipidemia. Similarly, a study 
using 2009 MEPS data also found that hypertension and hyperlipidemia was the most 
frequent dyad.37 Based on the 2012 edition of the chartbook, 52.9% of Medicare 
beneficiaries had both hypertension and hyper-lipidemia.38 The present study found that 
having hyper-lipidemia added $4,851 in medical expenditures per year at the individual 
level, albeit this marginal increase was lower than it was for the other CVD-related 
comorbidities except for valvular disease ($4,453). This is a substantial economic burden to 
society because of the high prevalence of hypertension and hyperlipidemia. Because 
hypertension and hyperlipidemia are major CVD risk factors and often coexist, adults with 
hypertension and hyperlipidemia should adopt healthier lifestyles and adhere to prescribed 
medications to reduce their risk of CVD.39
In this study, having CHF was associated with the highest incremental medical expenditure 
in hypertensive adults for the 15 most common comorbidities. Annual total medical 
expenditures were $17,063 in persons with CHF and $9,683 in those without CHF, a 
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difference of $7,380. Stroke and CHD were ranked as the third and fourth most costly 
comorbidities among the 15 most frequent, each adding approximately $6,000. Among 
Medicare beneficiaries, hypertension, hyperlipidemia, and ischemic heart disease, together, 
was the most prevalent triad with a prevalence of 33.7%.38 In addition, approximately 55% 
of Medicare beneficiaries with stroke and heart failure had five or more additional chronic 
health conditions. As such, a patient with stroke or heart failure also had many other 
conditions contributing to the overall difference in expenditures.38 Hypertension is an 
independent risk factor for both stroke and CHD. Moreover, appropriate hypertension 
treatment has been found to reduce the incidence of CHF by >50%, of stroke by 30%–40%, 
and of myocardial infarction by 20%–25%.40–42 Thus, the appropriate management of 
hypertension, by itself, can reduce the economic burdens to society. Furthermore, such 
management can decrease the prevalence of these CVDs and reduce overall medical 
expenditures incurred.
Diabetes is closely related to hypertension. Indeed, hypertension and diabetes share several 
biological and environmental risk factors, and they frequently occur together.43 In this study, 
diabetes was the second most common comorbidity; 27.3% of hypertensive adults also had 
diabetes. Similarly, in a study using 2009 MEPS data, diabetes with hypertension and 
hyperlipidemia was the most frequent triad.37 In addition, a previous study found that the 
prevalence of diabetes in a hypertensive population was 27%.44 In the whole population, a 
previous study using the MEPS data reported that the prevalence of diabetes was 8%.45 
Thus, the prevalence of diabetes in hypertensive adults seems to be roughly three times that 
seen in the general population. Because of the higher prevalence of diabetes in persons with 
hypertension, managing diabetes and hypertension together could be an effective way to 
reduce the economic burden on society. A community health workers program may be a 
good example.46
Hypertension and renal disease are interrelated, and hypertension may cause or result from 
renal disease.47,48 In previous studies, although the prevalence of hypertension varied in 
patients with renal disease, hypertension was present in up to 90% of such patients.49–51 
Management of hypertension is more difficult when there is poorer renal function. This 
study found that renal disease is not only a frequent comorbidity but also a costly problem in 
hypertensive adults. Implementing effective awareness and prevention programs for renal 
disease could help to reduce costs in hypertensive adults with renal disease and respond to 
public health demand.52
In this study, depression was the fourth most common comorbidity in adults with 
hypertension, affecting one fourth of this population. This result is quite similar to that 
obtained by a meta-analysis published in 2015 that found the prevalence of depression to be 
26.8% in patients with hypertension.53 Depression is known to have a negative impact on 
health outcomes in patients with hypertension.21,54,55 The present study found that the 
presence of depression increased expenditures by just under $5,000. Thus, effective 
screening for depression and appropriate monitoring of this disorder is important in caring 
for hypertensive patients. In addition, education in self-management can be a solution to 
empowering patients to reduce blood pressure and reduce stress and depressive feelings.
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Efforts to prevent and control hypertension are critical because hypertension is a major risk 
factor for heart disease, stroke, and renal disease. In this study, CHF, stroke, CHD, and renal 
disease were all in the top expenditures category. Hypertension can be better controlled by 
several approaches, including diet, nutritional supplements, lifestyle modification, and 
conventional antihypertensive medications.56 The Community Guide has found several 
strategies to be effective for hypertension prevention and control, including self-measured 
blood pressure, community health workers, clinical decision support systems, reducing out-
of-pocket costs for clinical services, and team-based care.57–59 In addition, managing 
obesity could be one of the effective ways for controlling of hypertension and other chronic 
conditions.60 Furthermore, appropriate hypertension management strategies should be 
developed for hypertensive adults with rheumatoid arthritis, depression, and chronic 
pulmonary diseases. Although these conditions are not directly associated with 
hypertension, these are frequent comorbidities in hypertensive adults. Nevertheless, little is 
known about the evidence on hypertension management strategies with these comorbidities.
This study had several strengths. First, the sample used was large, with a nationally 
representative database. The large sample enabled exploration into detailed comorbidity 
status and its impact on medical expenditures. Second, this study used a modified EI, 
expanding the list of CVD-related diseases to include such disorders as CHD, stroke, and 
hyperlipidemia. To the authors’ knowledge, this is the only study focusing on issues of 
comorbidity among hypertensive adults. Finally, a rigorous empirical approach that specified 
various regression models for the estimation was employed, which were able to control for 
various covariates.
Limitations
This study had several limitations. First, the data used were cross-sectional, and thus the 
authors can only claim that the medical expenditures were disease-associated although 
acknowledging that they may not have been the treatment costs for each specific disease. 
Furthermore, the impact of each comorbidity on the total medical expenditures cannot be 
interpreted as hypertension-associated. The purpose of this study was to determine how 
much the comorbidity increased the annual total medical expenditures in hypertensive 
adults. Second, MEPS does not include institutionalized persons in its database. Such people 
may have many serious comorbidities, and thus this study no doubt underestimated the 
percentage of hypertensive adults in the U.S. with comorbidities and therefore the associated 
direct medical costs. Third, because MEPS is a national survey, there is a possibility of recall 
bias. Respondents might not be able to correctly provide certain types of information, such 
as medical history. Fourth, this study did not investigate indirect costs, such as caregiver 
burden and absenteeism. Further research may be needed to examine the impact of 
comorbidity on productivity loss and the associated indirect costs in adults with 
hypertension. Fifth, the outcome variable was annual total medical expenditures including 
any types of medical services. For future studies, analyzing the breakdown of total medical 
expenditures by the type of services, such as inpatient hospitalizations, outpatient visits, 
emergency department visits, office-based physician visits, home health-care visits, and 
prescription medications could provide additional insights about cost burdens and guide 
intervention efforts. Finally, it was found that being a current nonsmoker was associated 
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with higher annual medical expenditures among hypertensive adults, compared with being a 
current smoker. However, it is previously known that smoking in hypertensive adults, 
including former smokers, was associated with increased medical expenditures.61 In MEPS, 
there is no information about smoking history. The most likely explanation is that 
hypertensive adults who are sick, with higher expenditures, are more likely to quit smoking.
CONCLUSIONS
Comorbidities were highly prevalent among U.S. hypertensive adults, and each successive 
comorbidity significantly increased the medical expenditures. The expenditure increases 
varied by the type and number of comorbidities. These findings illustrate the importance of 
looking at the impact of comorbidities and can be used to help develop and evaluate 
interventions for hypertension prevention and control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Fifteen most frequent comorbid conditions in U.S. hypertensive adults, 2011–2014 Medical 
Expenditure Panel Survey (n=26,049).
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Figure 2. 
Estimated annual medical expenditures (2014 USD) for nine hypertension-related comorbid 
conditions among the 15 most frequent comorbid conditions in U.S. hypertensive adults, 
2011–2014 Medical Expenditure Panel Survey.
Note: Mean annual total healthcare expenditures were estimated using the average marginal 
effects method from the generalized linear model (GLM) with log link and gamma 
distribution.
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